Status:
COMPLETED
Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells
Lead Sponsor:
University of North Carolina, Chapel Hill
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Confirmed diagnosis of MS
- Age 18-60 years, inclusive
- Expanded disability status of 0-6.5
- Give written informed consent prior to any testing under this protocol
Exclusion
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 15 2011
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00630721
Start Date
September 1 2007
End Date
March 15 2011
Last Update
October 18 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina
Chapel Hill, North Carolina, United States, 27599